Treatment Clinical Trials

MALIGNANT DISEASE
A221602: Olanzapine With or Without Fosaprepitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting (CINV) In Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, DoubleBlind, Placebo Controlled Trial Learn about the Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.

MALIGNANT DISEASE

A221602: Olanzapine With or Without Fosaprepitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting (CINV) In Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, DoubleBlind, Placebo Controlled Trial

Learn about the Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.

RARE TUMORS
S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Learn about Nivolumab and Ipilimumab in Treating Patients With Rare Tumors or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.

RARE TUMORS

S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Learn about Nivolumab and Ipilimumab in Treating Patients With Rare Tumors or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.